FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease - Associated Press https://t.co/5PJueIpVCO — IDRO (@IDROOhio) May 24, 2019
FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease - Associated Press https://t.co/5PJueIpVCO
No comments:
Post a Comment